Galina E. Chernukha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Galina E. Chernukha has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana V. Priputnevich
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health, 117997 Moscow, Russia
6 shared publications - Gennady Tikhonovich Sukhikh
National Medical Research Center for Obstetrics Gynecology and Perinatology Named after Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation, 117997 Moscow, Russia
5 shared publications V P Smetnik
5 shared publications- Aleksey V. Skorobogatiy
National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation, 117997 Moscow, Russia
4 shared publications - Antonina A. Smetnik
Department of Gynecological Endocrinology, National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of the Russian Federation, Moscow, Russia
4 shared publications - Elena N. Andreeva
Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
Factors Associated with Live Birth After Placenta-Derived Mesenchymal Stromal Cell Therapy in Women with Recurrent Intrauterine Adhesions and Thin Endometrium
Recurrent intrauterine adhesions (IUA) and refractory thin endometrium are associated with impaired endometrial regeneration, reduced implantation, and poor live birth outcomes. Regenerative therapy using mesenchymal stromal cells (MSCs) has shown promising results; however, factors associated with reproductive success remain unclear. In this prospective, single-centre, single-arm uncontrolled observational study, 35 women with recurrent IUA and thin endometrium (p = 0.04), lower baseline RI in uterine, arcuate and radial arteries, and higher baseline AMH (OR 2.59 per doubling; 95% CI 1.15–6.89) were significantly associated with live birth. Endometrial thickness increased after therapy but was not significantly associated with live birth. No severe adverse events were observed. Placenta-derived MSC therapy was followed by live birth in 31.4% of women with recurrent IUA and refractory thin endometrium. A shorter duration of reproductive disorders, less severe adhesions, lower baseline RI in uterine, arcuate and radial arteries, and higher AMH levels were associated with live birth after treatment and may help identify patients with a more favourable reproductive prognosis in future controlled studies.
Open AccessFactors Associated with Live Birth After Placenta-Derived Mesenchymal Stromal Cell Therapy in Women with Recurrent Intrauterine Adhesions and Thin Endometrium
Recurrent intrauterine adhesions (IUA) and refractory thin endometrium are associated with impaired endometrial regeneration, reduced implantation, and poor live birth outcomes. Regenerative therapy using mesenchymal stromal cells (MSCs) has shown promising results; however, factors associated with reproductive success remain unclear. In this prospective, single-centre, single-arm uncontrolled observational study, 35 women with recurrent IUA and thin endometrium (p = 0.04), lower baseline RI in uterine, arcuate and radial arteries, and higher baseline AMH (OR 2.59 per doubling; 95% CI 1.15–6.89) were significantly associated with live birth. Endometrial thickness increased after therapy but was not significantly associated with live birth. No severe adverse events were observed. Placenta-derived MSC therapy was followed by live birth in 31.4% of women with recurrent IUA and refractory thin endometrium. A shorter duration of reproductive disorders, less severe adhesions, lower baseline RI in uterine, arcuate and radial arteries, and higher AMH levels were associated with live birth after treatment and may help identify patients with a more favourable reproductive prognosis in future controlled studies.
- Open Access
- 11 January 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (4) , 21-37
Сlinical recommendations of RSOG "Menopause and climacteric period among females. Version of year 2025"
The present article contains the most actual version of Russian national clinical recommendations (Version of year 2025) "Menopause and climacteric period among females" In case of ignoring timely sex steroid replacement therapy menopause can decrease chances for achieving healthy longevity and ageing. This document has been provided by members of Russian Society of Obstetricicians and Gynaecologists (RSOG). The next revision is planned for year 2027 or earlier. The document has been approved by scientific practical council of the Russian Ministry of Health.
- 11 January 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (4) , 21-37
Open AccessСlinical recommendations of RSOG "Menopause and climacteric period among females. Version of year 2025"
The present article contains the most actual version of Russian national clinical recommendations (Version of year 2025) "Menopause and climacteric period among females" In case of ignoring timely sex steroid replacement therapy menopause can decrease chances for achieving healthy longevity and ageing. This document has been provided by members of Russian Society of Obstetricicians and Gynaecologists (RSOG). The next revision is planned for year 2027 or earlier. The document has been approved by scientific practical council of the Russian Ministry of Health.
- Open Access
- 5 November 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (3) , 28-39
Russian national clinical recommendations «Polycystic ovary syndrome». Version of 2025 year
The present article contains the most actual version of the Russian national clinical recommendations «Polycystic ovary syndrome» (2025 year). Polycystic ovary syndrome (PCOS) is the most common reproductive and hormonal disease among reproductive age females. The incidence of this disease varies from 8% until 21% of females. The present recommendations have been published due to collaboration between Russian Society of Obstetricians and Gynecologists and Russian Association of Endocrinologists. The next revision is planned for year 2028 or earlier (due to potential appearance of new evidence criteria). The document has been approved by scientific practical council of the Russian Ministry of Health.
- 5 November 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (3) , 28-39
Open AccessRussian national clinical recommendations «Polycystic ovary syndrome». Version of 2025 year
The present article contains the most actual version of the Russian national clinical recommendations «Polycystic ovary syndrome» (2025 year). Polycystic ovary syndrome (PCOS) is the most common reproductive and hormonal disease among reproductive age females. The incidence of this disease varies from 8% until 21% of females. The present recommendations have been published due to collaboration between Russian Society of Obstetricians and Gynecologists and Russian Association of Endocrinologists. The next revision is planned for year 2028 or earlier (due to potential appearance of new evidence criteria). The document has been approved by scientific practical council of the Russian Ministry of Health.
- Open Access
- 1 August 2025
- Published by MDPI AG in Microbiology Research
- Vol. 16 (8) , 169
Gut Microbial Composition on Dienogest Therapy in Patients with Endometriosis
Endometriosis is a chronic inflammatory condition affecting approximately 10% of women of reproductive age, characterized by pelvic pain, dysmenorrhea, and infertility. Emerging evidence suggests a potential link between gut microbiota dysbiosis and endometriosis pathogenesis, mediated through hormonal regulation, immune modulation, and systemic inflammation. Dienogest (DNG) is widely used for endometriosis management, but its effects on gut microbiota remain underexplored. This study investigates the impact of DNG on gut microbial composition in endometriosis patients, aiming to elucidate its therapeutic mechanisms beyond hormonal modulation. DNG therapy led to a significant reduction in the Bacillota/Bacteroidota ratio (p = 0.0421), driven by decreased Staphylococcus spp. (p = 0.0244) and increased commensal bacteria such as Lactobacillus spp. and Collinsella aerofaciens (p = 0.049). Species richness and alpha diversity indices showed a non-significant upward trend. Notably, C. aerofaciens, a butyrate producer linked to gut barrier integrity, was detected twice as frequently during therapy. The study also observed reductions in facultative anaerobes like Enterococcus spp. and a trend toward higher titers of beneficial Bacteroidota. This study provides the first evidence that DNG therapy modulates gut microbiota in endometriosis patients, favoring a composition associated with anti-inflammatory and barrier-protective effects. The observed shifts—reduced opportunistic pathogens and increased symbionts—suggest a novel mechanism for DNG’s efficacy, potentially involving the microbial regulation of estrogen metabolism and immune responses.
- 1 August 2025
- Published by MDPI AG in Microbiology Research
- Vol. 16 (8) , 169
Open AccessGut Microbial Composition on Dienogest Therapy in Patients with Endometriosis
Endometriosis is a chronic inflammatory condition affecting approximately 10% of women of reproductive age, characterized by pelvic pain, dysmenorrhea, and infertility. Emerging evidence suggests a potential link between gut microbiota dysbiosis and endometriosis pathogenesis, mediated through hormonal regulation, immune modulation, and systemic inflammation. Dienogest (DNG) is widely used for endometriosis management, but its effects on gut microbiota remain underexplored. This study investigates the impact of DNG on gut microbial composition in endometriosis patients, aiming to elucidate its therapeutic mechanisms beyond hormonal modulation. DNG therapy led to a significant reduction in the Bacillota/Bacteroidota ratio (p = 0.0421), driven by decreased Staphylococcus spp. (p = 0.0244) and increased commensal bacteria such as Lactobacillus spp. and Collinsella aerofaciens (p = 0.049). Species richness and alpha diversity indices showed a non-significant upward trend. Notably, C. aerofaciens, a butyrate producer linked to gut barrier integrity, was detected twice as frequently during therapy. The study also observed reductions in facultative anaerobes like Enterococcus spp. and a trend toward higher titers of beneficial Bacteroidota. This study provides the first evidence that DNG therapy modulates gut microbiota in endometriosis patients, favoring a composition associated with anti-inflammatory and barrier-protective effects. The observed shifts—reduced opportunistic pathogens and increased symbionts—suggest a novel mechanism for DNG’s efficacy, potentially involving the microbial regulation of estrogen metabolism and immune responses.
- Open Access
- 1 January 2025
- Published by NP Rusmedical Group in Doctor.Ru
- Vol. 24 (1)
Comprehensive Study of Intestinal Microbiota Using Molecular Genetic and Cultural Methods with an Assessment of the Role of Fecal Biomarkers in Endometriosis
Aim. Analysis of the composition of intestinal microbiota in patients with endometriosis and determination of the potential value of fecal biomarkers in the diagnosis of the disease. Design. Сross-sectional, single-center clinical study. Materials and methods. The clinical and anamnestic data of 260 women with endometriosis (mean age 28 (25; 33) years) were analyzed. A comparison group of 130 age-matched women without signs of genital endometriosis was selected to study symptoms and comorbid conditions of endometriosis. In order to measure the concentrations of fecal markers, 56 women of the main group and 21 of the comparison group were randomized, fecal samples of 37 patients with endometriosis and 22 women of the comparison group were selected for microbiological examination. Microbiological examination of fecal samples was performed by culture and quantitative real-time polymerase chain reaction (PCR) methods, and the concentrations of fecal markers (calprotectin, hemoglobin, transferrin) were estimated by the HTSA Plus immunochemical method in the same biological material. Results. Every 4th patient with endometriosis had complaints of dyschezia (68/260, 26.2%), and more than 60% reported changes in stool character during menstruation in the form of loosening or constipation (161/260, 61.9%). Analysis of gastrointestinal tract (GIT) pathology showed that 77 (29.6%) patients had concomitant organic GIT diseases, i. e. 1.4 times more often than in the comparison group, 60 (23,1%) had irritable bowel syndrome (IBS). The presence of complaints of stool changes during menstruation increased the chances of diagnosing endometriosis 2-fold, concomitant IBS — 5-fold, and dyschezia more than 16-fold. Every 2nd patient with endometriosis (27/56, 48.2%) had a fecal calprotectin concentration greater than reference values, which was also positively correlated with symptoms of intestinal dysbiosis (r = 0.397, p = 0.0025). Analysis of the composition of the intestinal microbiota showed a decrease in species richness, an increase in the frequency and titer of opportunistic microorganisms and a decrease in the colonization of symbiont bacteria in endometriosis. The realtime PCR method had advantages for additional detection of complexly cultured microorganisms; a decrease in the titer of symbiont bacteria of the Clostridium leptum gr. cluster (p = 0.02808), Faecalibacterium prausnitzii (p = 0.03635) and Akkermansia muciniphila (p = 0.05297), microorganisms of the family of the genus Desulfovibrio (p = 0.04852) was detected. Conclusion. An important stage of clinical and anamnestic examination of patients with endometriosis, in addition to the detection of IBS, is the assessment of the presence of organic pathology of the gastrointestinal tract and a number of gastrointestinal symptoms, which can increase the chances of diagnosing endometriosis up to 16 times. Studying the composition of the intestinal microbiota in endometriosis is a promising direction, it is advisable to comprehensively determine the microbial composition by culture and quantitative real-time PCR methods using an extended multiplex panel. Measurement of faecal marker levels seems to be a promising but insufficiently studied method for non-invasive diagnosis of endometriosis, which requires additional studies with a larger sample of patients with colorectal endometriosis. Keywords: endometriosis, intestinal microbiota, culturomics, real-time polymerase chain reaction, faecal calprotectin.
- 1 January 2025
- Published by NP Rusmedical Group in Doctor.Ru
- Vol. 24 (1)
Open AccessComprehensive Study of Intestinal Microbiota Using Molecular Genetic and Cultural Methods with an Assessment of the Role of Fecal Biomarkers in Endometriosis
Aim. Analysis of the composition of intestinal microbiota in patients with endometriosis and determination of the potential value of fecal biomarkers in the diagnosis of the disease. Design. Сross-sectional, single-center clinical study. Materials and methods. The clinical and anamnestic data of 260 women with endometriosis (mean age 28 (25; 33) years) were analyzed. A comparison group of 130 age-matched women without signs of genital endometriosis was selected to study symptoms and comorbid conditions of endometriosis. In order to measure the concentrations of fecal markers, 56 women of the main group and 21 of the comparison group were randomized, fecal samples of 37 patients with endometriosis and 22 women of the comparison group were selected for microbiological examination. Microbiological examination of fecal samples was performed by culture and quantitative real-time polymerase chain reaction (PCR) methods, and the concentrations of fecal markers (calprotectin, hemoglobin, transferrin) were estimated by the HTSA Plus immunochemical method in the same biological material. Results. Every 4th patient with endometriosis had complaints of dyschezia (68/260, 26.2%), and more than 60% reported changes in stool character during menstruation in the form of loosening or constipation (161/260, 61.9%). Analysis of gastrointestinal tract (GIT) pathology showed that 77 (29.6%) patients had concomitant organic GIT diseases, i. e. 1.4 times more often than in the comparison group, 60 (23,1%) had irritable bowel syndrome (IBS). The presence of complaints of stool changes during menstruation increased the chances of diagnosing endometriosis 2-fold, concomitant IBS — 5-fold, and dyschezia more than 16-fold. Every 2nd patient with endometriosis (27/56, 48.2%) had a fecal calprotectin concentration greater than reference values, which was also positively correlated with symptoms of intestinal dysbiosis (r = 0.397, p = 0.0025). Analysis of the composition of the intestinal microbiota showed a decrease in species richness, an increase in the frequency and titer of opportunistic microorganisms and a decrease in the colonization of symbiont bacteria in endometriosis. The realtime PCR method had advantages for additional detection of complexly cultured microorganisms; a decrease in the titer of symbiont bacteria of the Clostridium leptum gr. cluster (p = 0.02808), Faecalibacterium prausnitzii (p = 0.03635) and Akkermansia muciniphila (p = 0.05297), microorganisms of the family of the genus Desulfovibrio (p = 0.04852) was detected. Conclusion. An important stage of clinical and anamnestic examination of patients with endometriosis, in addition to the detection of IBS, is the assessment of the presence of organic pathology of the gastrointestinal tract and a number of gastrointestinal symptoms, which can increase the chances of diagnosing endometriosis up to 16 times. Studying the composition of the intestinal microbiota in endometriosis is a promising direction, it is advisable to comprehensively determine the microbial composition by culture and quantitative real-time PCR methods using an extended multiplex panel. Measurement of faecal marker levels seems to be a promising but insufficiently studied method for non-invasive diagnosis of endometriosis, which requires additional studies with a larger sample of patients with colorectal endometriosis. Keywords: endometriosis, intestinal microbiota, culturomics, real-time polymerase chain reaction, faecal calprotectin.
- Open Access
- 2 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10636
Impact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy
Polycystic ovary syndrome (PCOS) is a complex disorder that impacts both the endocrine and metabolic systems, often resulting in infertility, obesity, insulin resistance, and cardiovascular complications. The aim of this study is to investigate the role of intestinal flora and its metabolites, particularly short-chain fatty acids (SCFAs), in the development of PCOS, and to assess the effects of metformin therapy on these components. SCFA levels in fecal and blood samples from women with PCOS () and healthy controls () were analyzed using Gas Chromatography–Mass Spectrometry (GC/MS) for precise measurement. Fecal microbiota were quantitatively detected by real-time polymerase chain reaction (PCR). To assess the efficacy of six months of metformin treatment, changes in the microbiota and SCFAs in the PCOS group () were also evaluated. The results revealed that women with PCOS exhibited a significant reduction in beneficial bacteria (namely, the C. leptum group and Prevotella spp.) alongside a notable overgrowth of opportunistic microorganisms (C. perfringens, C. difficile, Staphylococcus spp., and Streptococcus spp.). An overproduction of acetic acid (AA, , ) and valeric acid (VA, , ) suggests a link between elevated SCFAs and the development of obesity and PCOS. Interestingly, AA in the bloodstream might offer a protective effect against PCOS by ameliorating key symptoms such as high body mass index (, ), insulin resistance (, ), and chronic inflammation. Although serum SCFA levels showed non-significant changes following metformin treatment (), the normalization of AA in the gut underscores that metformin exerts a more pronounced effect locally within the gastrointestinal tract. Furthermore, the study identified the most effective model for predicting the success of metformin therapy, based on serum concentrations of butyric acid (BA) and VA, achieving a 91% accuracy rate, 100% sensitivity, and 80% specificity. These promising findings highlight the potential for developing targeted interventions and personalized treatments, ultimately improving clinical outcomes for women with PCOS.- 2 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10636
Open AccessImpact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy
Polycystic ovary syndrome (PCOS) is a complex disorder that impacts both the endocrine and metabolic systems, often resulting in infertility, obesity, insulin resistance, and cardiovascular complications. The aim of this study is to investigate the role of intestinal flora and its metabolites, particularly short-chain fatty acids (SCFAs), in the development of PCOS, and to assess the effects of metformin therapy on these components. SCFA levels in fecal and blood samples from women with PCOS () and healthy controls () were analyzed using Gas Chromatography–Mass Spectrometry (GC/MS) for precise measurement. Fecal microbiota were quantitatively detected by real-time polymerase chain reaction (PCR). To assess the efficacy of six months of metformin treatment, changes in the microbiota and SCFAs in the PCOS group () were also evaluated. The results revealed that women with PCOS exhibited a significant reduction in beneficial bacteria (namely, the C. leptum group and Prevotella spp.) alongside a notable overgrowth of opportunistic microorganisms (C. perfringens, C. difficile, Staphylococcus spp., and Streptococcus spp.). An overproduction of acetic acid (AA, , ) and valeric acid (VA, , ) suggests a link between elevated SCFAs and the development of obesity and PCOS. Interestingly, AA in the bloodstream might offer a protective effect against PCOS by ameliorating key symptoms such as high body mass index (, ), insulin resistance (, ), and chronic inflammation. Although serum SCFA levels showed non-significant changes following metformin treatment (), the normalization of AA in the gut underscores that metformin exerts a more pronounced effect locally within the gastrointestinal tract. Furthermore, the study identified the most effective model for predicting the success of metformin therapy, based on serum concentrations of butyric acid (BA) and VA, achieving a 91% accuracy rate, 100% sensitivity, and 80% specificity. These promising findings highlight the potential for developing targeted interventions and personalized treatments, ultimately improving clinical outcomes for women with PCOS. - Open Access
- 20 September 2024
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 26 (3) , 260-269
Heavy menstrual bleeding and anemia: The problem is growing and requires a solution. A review
Anemia is a global health problem, affecting about a quarter of the world's population, especially women of reproductive age and young children. In 50–75% of cases, anemia is secondary to iron deficiency (ID). Despite the high prevalence of heavy menstrual bleeding (HMB), the associated iron deficiency disorders are underestimated, although they sharply reduce the quality of life and carry significant risks for the mother, fetus and newborn in case of pregnancy. For this purpose, routine screening of girls and women of reproductive age for the presence of ID and anemia is recommended. The new FIGO initiative aims to raise awareness among women and clinicians about the relationship between HMB and ID conditions. Of key importance are: early diagnosis of HMB, elimination of the possible cause, identification of associated iron deficiency disorders, especially preclinical forms. The main task of the gynecologist is to prescribe therapy aimed at quickly stopping high monthly iron losses and replenishing the existing ID. According to Russian clinical guidelines, combined oral contraceptives and an intrauterine system with levonorgestrel are considered first-line therapy to reduce the volume of menstrual blood loss in patients with HMB who require contraception. Qlaira® and Mirena® are the only hormonal drugs registered for contraception and the treatment of HMB not associated with structural disorders of the uterus, since their high effectiveness in reducing menstrual blood loss, restoring hemoglobin and ferritin levels has been confirmed in studies with a high level of evidence.
- 20 September 2024
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 26 (3) , 260-269
Open AccessHeavy menstrual bleeding and anemia: The problem is growing and requires a solution. A review
Anemia is a global health problem, affecting about a quarter of the world's population, especially women of reproductive age and young children. In 50–75% of cases, anemia is secondary to iron deficiency (ID). Despite the high prevalence of heavy menstrual bleeding (HMB), the associated iron deficiency disorders are underestimated, although they sharply reduce the quality of life and carry significant risks for the mother, fetus and newborn in case of pregnancy. For this purpose, routine screening of girls and women of reproductive age for the presence of ID and anemia is recommended. The new FIGO initiative aims to raise awareness among women and clinicians about the relationship between HMB and ID conditions. Of key importance are: early diagnosis of HMB, elimination of the possible cause, identification of associated iron deficiency disorders, especially preclinical forms. The main task of the gynecologist is to prescribe therapy aimed at quickly stopping high monthly iron losses and replenishing the existing ID. According to Russian clinical guidelines, combined oral contraceptives and an intrauterine system with levonorgestrel are considered first-line therapy to reduce the volume of menstrual blood loss in patients with HMB who require contraception. Qlaira® and Mirena® are the only hormonal drugs registered for contraception and the treatment of HMB not associated with structural disorders of the uterus, since their high effectiveness in reducing menstrual blood loss, restoring hemoglobin and ferritin levels has been confirmed in studies with a high level of evidence.
- Open Access
- 4 September 2024
- Published by MDPI AG in Preprints.org
Impact of Gut Microbiota and SCFAs in PCOS Pathogenesis and Metformin on Therapy
Polycystic ovary syndrome (PCOS) is a complex disorder that impacts both the endocrine and metabolic systems. The gut microbiota plays a crucial role in in metabolism regulation and immune responses through its interaction with the external environment. This article explores the intricate interplay between intestinal flora and the pathogenesis of PCOS, focusing on the pivotal role of microbial metabolites, specifically short-chain fatty acids (SCFAs). SCFA levels in fecal and blood samples from women with PCOS (n=69) and healthy controls (n=18) were analyzed using Gas Chromatography-Mass Spectrometry (GC/MS) for precise measurement. The results revealed that women with PCOS exhibited a significant reduction in beneficial bacteria alongside a notable overgrowth of opportunistic microorganisms. An overproduction of acetic acid (AA) and valeric acid (VA) in fecal samples suggests a link between elevated SCFAs and the development of obesity and PCOS. Interestingly, AA in the bloodstream might offer a protective effect against PCOS by ameliorating key symptoms such as high body mass index (BMI), insulin resistance (IR), and chronic inflammation. This finding points to the potential therapeutic value of maintaining optimal AA levels in the blood. Although serum SCFA levels showed non-significant changes following metformin treatment, the normalization of AA in the gut underscores that metformin exerts a more pronounced effect locally within the gastrointestinal tract. This treatment also led to an increase in beneficial gut bacteria and a reduction in opportunistic pathogens, suggesting a restoration of gut microbial balance. Furthermore, the study identified the most effective model for predicting the success of metformin therapy, based on serum concentrations of butyric acid (BA) and VA, achieving a 91% accuracy rate, 100% sensitivity, and 80% specificity. These promising findings highlight the potential for developing targeted interventions and personalized treatments, ultimately improving clinical outcomes for women with PCOS.
- 4 September 2024
- Published by MDPI AG in Preprints.org
Open AccessImpact of Gut Microbiota and SCFAs in PCOS Pathogenesis and Metformin on Therapy
Polycystic ovary syndrome (PCOS) is a complex disorder that impacts both the endocrine and metabolic systems. The gut microbiota plays a crucial role in in metabolism regulation and immune responses through its interaction with the external environment. This article explores the intricate interplay between intestinal flora and the pathogenesis of PCOS, focusing on the pivotal role of microbial metabolites, specifically short-chain fatty acids (SCFAs). SCFA levels in fecal and blood samples from women with PCOS (n=69) and healthy controls (n=18) were analyzed using Gas Chromatography-Mass Spectrometry (GC/MS) for precise measurement. The results revealed that women with PCOS exhibited a significant reduction in beneficial bacteria alongside a notable overgrowth of opportunistic microorganisms. An overproduction of acetic acid (AA) and valeric acid (VA) in fecal samples suggests a link between elevated SCFAs and the development of obesity and PCOS. Interestingly, AA in the bloodstream might offer a protective effect against PCOS by ameliorating key symptoms such as high body mass index (BMI), insulin resistance (IR), and chronic inflammation. This finding points to the potential therapeutic value of maintaining optimal AA levels in the blood. Although serum SCFA levels showed non-significant changes following metformin treatment, the normalization of AA in the gut underscores that metformin exerts a more pronounced effect locally within the gastrointestinal tract. This treatment also led to an increase in beneficial gut bacteria and a reduction in opportunistic pathogens, suggesting a restoration of gut microbial balance. Furthermore, the study identified the most effective model for predicting the success of metformin therapy, based on serum concentrations of butyric acid (BA) and VA, achieving a 91% accuracy rate, 100% sensitivity, and 80% specificity. These promising findings highlight the potential for developing targeted interventions and personalized treatments, ultimately improving clinical outcomes for women with PCOS.
- Open Access
- 15 July 2024
- Published by Astrakhan State Medical University in Astrakhan Medical Journal
- Vol. 19 (2) , 78-84
The effect of oral progestogens on the intestinal microbiota composition in patients with endometriosis: pilot study
Today, the contribution of the microbiota to the genesis of many diseases, including endometriosis, is widely discussed. However, the literature data on the microbiological composition of endometriosis are contradictory. In addition, data indicating the effect of conservative therapy on the microbiological composition are limited only to estrogen-containing drugs, while there is no data on the effect of progestogens. Objective: to evaluate the composition of the intestinal microbiota of patients with external genital endometriosis on oral progestogen therapy. A single-stage pilot study was conducted, which included 17 patients with external genital endometriosis (average age 30.9 (7.8) years, average body mass index 20.2 (2.0) kg/m2 ). The women received oral progestogen therapy (dienogest at a dose of 2 mg per day in a continuous mode). Microbiological examination of faecal samples by culturomics methods with inoculation on selective and non-selective nutrient media, followed by species identification of microorganisms, was carried out using time-of-flight mass spectrometry (MALDI-TOF MS) at two points: initially and after 6 months of taking dienogest. Dienogest therapy showed an improvement in a number of microbiological indicators of the intestinal microbiota in the form of a tendency to increase species and taxonomic diversity, a decrease in the Bacillota / Bacteroidota index, and a decrease in the titer of conditionally pathogenic microorganisms Staphylococcus spp. and increased colonization of symbiotic bacteria of the Collinsella aerofaciens and Lactobacillus spp. Thus, dienogest therapy can have both a direct and indirect effect on the composition of the intestinal microbiota of patients with external genital endometriosis, which was demonstrated by the results of the study.
- 15 July 2024
- Published by Astrakhan State Medical University in Astrakhan Medical Journal
- Vol. 19 (2) , 78-84
Open AccessThe effect of oral progestogens on the intestinal microbiota composition in patients with endometriosis: pilot study
Today, the contribution of the microbiota to the genesis of many diseases, including endometriosis, is widely discussed. However, the literature data on the microbiological composition of endometriosis are contradictory. In addition, data indicating the effect of conservative therapy on the microbiological composition are limited only to estrogen-containing drugs, while there is no data on the effect of progestogens. Objective: to evaluate the composition of the intestinal microbiota of patients with external genital endometriosis on oral progestogen therapy. A single-stage pilot study was conducted, which included 17 patients with external genital endometriosis (average age 30.9 (7.8) years, average body mass index 20.2 (2.0) kg/m2 ). The women received oral progestogen therapy (dienogest at a dose of 2 mg per day in a continuous mode). Microbiological examination of faecal samples by culturomics methods with inoculation on selective and non-selective nutrient media, followed by species identification of microorganisms, was carried out using time-of-flight mass spectrometry (MALDI-TOF MS) at two points: initially and after 6 months of taking dienogest. Dienogest therapy showed an improvement in a number of microbiological indicators of the intestinal microbiota in the form of a tendency to increase species and taxonomic diversity, a decrease in the Bacillota / Bacteroidota index, and a decrease in the titer of conditionally pathogenic microorganisms Staphylococcus spp. and increased colonization of symbiotic bacteria of the Collinsella aerofaciens and Lactobacillus spp. Thus, dienogest therapy can have both a direct and indirect effect on the composition of the intestinal microbiota of patients with external genital endometriosis, which was demonstrated by the results of the study.
- Open Access
- 25 March 2024
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 3 (1) , 9-67
National medical eligibility criteria for contraceptive use 2023: review
Individual sexual and reproductive life management has been сonfirmed by medical and state communities since 1990s. Every citizen officially received rights for access to appropriate goods and services. Such international agreements as 1994 International Conference on Population and Development (ICPD, Cairo, Egypt) and 2004 WHO Reproductive health strategy, estimated reproductive health and family planning as priorities. Worldwide agreement on the 2005 summit declares achieving of female reproductive health before year 2015 as worldwide progress.WHO created complex of international eligibility criteria for male and female contraception with the aim of medical aid improvement. According to WHO plan, those criteria should be used by countries considering policy, needs, priorities and resources of national healthcare programs. For example, USA, United Kingdom, Russia etc. have successfully adopted medical eligibility criteria for contraception on the national level.The present review is summary product created by interdisciplinary expert group including representers of federal and regional healthcare establishments, medical universities, and international medical organizations.
- 25 March 2024
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 3 (1) , 9-67
Open AccessNational medical eligibility criteria for contraceptive use 2023: review
Individual sexual and reproductive life management has been сonfirmed by medical and state communities since 1990s. Every citizen officially received rights for access to appropriate goods and services. Such international agreements as 1994 International Conference on Population and Development (ICPD, Cairo, Egypt) and 2004 WHO Reproductive health strategy, estimated reproductive health and family planning as priorities. Worldwide agreement on the 2005 summit declares achieving of female reproductive health before year 2015 as worldwide progress.WHO created complex of international eligibility criteria for male and female contraception with the aim of medical aid improvement. According to WHO plan, those criteria should be used by countries considering policy, needs, priorities and resources of national healthcare programs. For example, USA, United Kingdom, Russia etc. have successfully adopted medical eligibility criteria for contraception on the national level.The present review is summary product created by interdisciplinary expert group including representers of federal and regional healthcare establishments, medical universities, and international medical organizations.